Table 2. SARS-CoV 2 Anti-S IgG Titer Values by Group, Cancer Type, and Anticancer Treatment.
| Characteristic | Patients with cancer (n = 102) | Controls (n = 78) | P value | ||
|---|---|---|---|---|---|
| Seropositive, No. (%) | 92 (90) | 78 (100) | |||
| IgG titer values | No. | Median (IQR) [range] | No. | Median (IQR) [range] | |
| All | 102 | 1931 (509-4386) [0.3-53 088] | 78 | 7160 (3129-11 241) [442-27 568] | <.001 |
| Cancer type | |||||
| Gastrointestinal | 29 | 983 (363-2291) [3-26 129] | NA | NA | NA |
| Lung | 26 | 1334 (337-4752) [0.3-45 612] | |||
| Breast | 18 | 2966 (957-7828) [6.5-32 145] | |||
| Other | 12 | 4354 (3096-7789) [980-53 088] | |||
| Brain | 9 | 1675 (1090-2306) [189-4387] | |||
| Genitourinary | 8 | 1942 (1058-3099) [11-5132] | |||
| Treatment | |||||
| Chemotherapy | 30 | 1363 (738-4166) [6.5-53 088] | NA | NA | NA |
| Immunotherapy | 22 | 3020 (1411-5370) [56-26 054] | |||
| Chemotherapy + biological therapy | 20 | 1842 (444-5080) [3-32 145] | |||
| Chemotherapy + immunotherapy | 14 | 310 (58.5-1811) [0.3-30 985] | |||
| Biological therapy | 11 | 3444 (2137-6964) [189-11 283] | |||
| Immunotherapy + biological therapy | 5 | 521 (505-2962) [11-3988] | |||
Abbreviations: anti-S, antispike; IQR, interquartile range; NA, not applicable.